Condition
Duration of Response
Total Trials
3
Recruiting
0
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
P 1 (1)
Trial Status
Not Yet Recruiting1
Unknown1
Active Not Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT07542912Not ApplicableNot Yet Recruiting
Sintilimab, Chidamide, and Azacitidine for Untreated Stage I-II Extranodal NK/T-Cell Lymphoma
NCT07099222Phase 1Active Not Recruiting
Efficacy of Non-weight Based, Low Dose Dex-Dex Adjuncts in Prolonging Peripheral Nerve Blocks
NCT03892577Unknown
Real-world Study for Patients With Advanced Hepatobiliary Tumors
Showing all 3 trials